AC
Arcellx
ACLX·NASDAQRedwood City CAFounded 2015200 employees
Mid CapbiotechPublicOncologyHematology
Platform: ddCAR-T Anito
Market Cap
$3.5B
All Drugs
3
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (ACLX)
Loading ACLX stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Cevifutibatinib | ACL-9317 | Phase 1 | 1 | BCL-2 | PompeACC | ||
| Riluzasiran | ACL-5354 | Phase 2/3 | 1 | SHP2 | NSCLCEpilepsy | ||
| ACL-6459 | ACL-6459 | Phase 3 | 4 | FGFR | FLADPKD |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (4)